Sean A. McCarthy

President, Chief Executive Officer & Chairman at CytomX Therapeutics, Inc.

Sean A. McCarthy

Sean A. McCarthy

President, Chief Executive Officer & Chairman at CytomX Therapeutics, Inc.

Overview
Career Highlights

CytomX Therapeutics Holdings LLC
CytomX Therapeutics, Inc.

RelSci Relationships

1066

Number of Boards

8

Birthday

1967

Age

53

Relationships
RelSci Relationships are individuals Sean A. McCarthy likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Lunglife AI, Inc.

Relationship likelihood: Strong

Professor, BioMolecular Science & Engineering at University of California - Santa Barbara

Relationship likelihood: Strong

Co-Founder, Director at Lunglife AI, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Alnylam Pharmaceuticals, Inc.

Relationship likelihood: Strong

Senior Vice President, Chief Scientific Officer, Head of Research & Non-Clinical Development at CytomX Therapeutics, Inc.

Relationship likelihood: Strong

Former Interim Executive Chairman at Geron Corp.

Relationship likelihood: Strong

Partner at Third Rock Ventures LLC

Relationship likelihood: Strong

Managing General Partner at Pappas Capital LLC

Relationship likelihood: Strong

Former Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc.

Relationship likelihood: Strong

Board of Executive Chairman at Spyryx Biosciences, Inc.

Relationship likelihood: Strong

Paths to Sean A. McCarthy
Potential Connections via
Relationship Science
You
Sean A. McCarthy
President, Chief Executive Officer & Chairman at CytomX Therapeutics, Inc.
Education
BS Biochemistry & Pharmacology

King's College London was founded by King George IV and the Duke of Wellington (then Prime Minister) in 1829 as a university college in the tradition of the Church of England. It now welcomes staff and students of all faiths and beliefs.

D.Phil. in Cancer Biology
Master of Business Administration

Founded in 2003 in response to the need for a business education that focuses on the industries that define our future and the transformation of business itself, the Rady School of Management is the leader of a new generation of business schools. Challenging the traditional business school model and situated at the confluence of business, science and technology, the Rady School MBA is an immersion in discovery and impact. The development of leaders who pursue the extraordinary, incubate new ideas, reinvent existing businesses and establish new companies is at the core of our curriculum and culture. As part of the University of California system, Rady students have access to one of the greatest centers of education and research in the world. Located in one of the world's fastest growing hubs of innovation, technology and new industries, the Rady School integrates the MBA curriculum with direct access to, and the opportunity to work with, world-renowned visionaries, business leaders and venture capitalists.

Career History
Chief Executive Officer
2011 - Current

CytomX Therapeutics Holdings LLC engaged in the development of new generation targeted antibody therapeutics. The company was founded by Frederick W. Gluck on January 31, 2008 and is headquartered in Santa Barbara, CA.

President, Chief Executive Officer & Chairman
2010 - Current

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Vice President of Business Development
2000 - 2011

SGX Pharmaceuticals, Inc. researches and develops drugs and other pharmaceutical products. The company was incorporated in June 20, 1999 and is headquartered in San Diego, CA.

Boards & Committees
Director
Current

California Biomedical Innovation Alliance is an American private company located in South San Francisco, CA, with operations in the United States. The firm provides biomedical advocacy and community services. Sara Radcliffe is currently the CEO of the company.The company says this about itself: California Life Sciences Association (CLSA) is the state’s largest and most influential life sciences advocacy and business leadership organization. With offices in Sacramento, San Diego, South San Francisco, Los Angeles and Washington DC, CLSA works closely with industry, government, academia and others to shape public policy, improve access to innovative technologies and grow California’s life sciences economy. CLSA serves bio technology, pharmaceutical, medical device and diagnostics companies, research universities and institutes, investors and service providers throughout the Golden State. CLSA was founded in 2015 when the Bay Area Bioscience Association (BayBio) and the California Healthcare Institute (CHI) merged.

Director
2011 - Prior

CytomX Therapeutics Holdings LLC engaged in the development of new generation targeted antibody therapeutics. The company was founded by Frederick W. Gluck on January 31, 2008 and is headquartered in Santa Barbara, CA.

Director
Prior

TYRX, Inc. designs and manufactures medical-pharmaceutical combination devices. The firm commercializes implantable combination drug and device products focused on infection control including the AIGISRx Antibacterial Envelope, designed to reduce surgical site infections associated with cardiac implantable electronic devices (CIEDs). Its AIGISRx products contain the antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by pathogens responsible for the majority of CIED infections, including superbugs such as methicillin-resistant S. aureus (MRSA). The company was founded in 1998 by Satish Pulapura and Arikha Moses and is headquartered in Monmouth Junction, NJ.

Transactions
Details Hidden

CytomX Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

CytomX Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

CytomX Therapeutics, Inc. raised money in a private placement transaction

Public Holdings
Restricted data only for RelSci Professional users.
Advisors
Special Advisor

Former Interim Executive Chairman at Geron Corp.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Sean A. McCarthy. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Sean A. McCarthy's profile does not indicate a business or promotional relationship of any kind between RelSci and Sean A. McCarthy.